SOURCE: Galapagos NV

October 26, 2007 12:02 ET

Galapagos creates new warrant plan

MECHELEN, BELGIUM--(Marketwire - October 26, 2007) - Galapagos NV (Euronext & LSE: GLPG) announced today that its Board of Directors has created and offered 114,100 warrants under a new warrant plan for Galapagos employees.

On 25 October 2007 the Board of Directors of Galapagos approved the "Warrant Plan 2007 RMV" within the framework of the authorized capital. Since its inception in 1999, Galapagos has used warrant plans to allow personnel and management to be involved in the company's growth and development. Under this new warrant plan 114,100 warrants were created and offered to employees of Galapagos' affiliate in Romainville (France). The warrants have an exercise period of eight years starting as of the date of the offer. They are not transferable and cannot be exercised prior to the end of the third calendar year after the year in which they were granted to a warrant holder. Each warrant gives the right to subscribe to one new Galapagos share. Should the warrants be exercised, Galapagos will apply for the listing of the resulting new shares on a regulated stock market. The warrants as such will not be admitted to listing on any stock market.


About Galapagos

Galapagos (Euronext Brussels, GLPG; Euronext Amsterdam, GLPGA; London AiM: GLPG) is a drug discovery company with pre-clinical programs in bone and joint diseases and cachexia. Its division BioFocus DPI offers a full suite of target-to-drug discovery products and services to pharmaceutical and biotech companies, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates. BioFocus DPI also provides adenoviral reagents for rapid identification and validation of novel drug targets, compound libraries for drug screening as well as chemogenomics and ADMET database products to select targets and compounds. Galapagos currently employs 460 people and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More information about Galapagos and BioFocus DPI can be found at www.glpg.com and www.biofocusdpi.com.



This release may contain forward-looking statements, including, without limitation, statements containing the words "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," and "continues," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.





Copyright © Hugin ASA 2007. All rights reserved.

Contact Information

  • CONTACT

    Galapagos NV
    Onno van de Stolpe, CEO
    Tel: +31 6 2909 8028
    ir@glpg.com